drugset / Trial / NCT01593254
Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
Phase 2
Completed
262 enrolled
Bristol-Myers Squibb
Donald E. Morisky · collabICON Clinical Research · collabMD Anderson Symptom Inventory (MDASI-CML) · collabMolecular MD · collabMultiPharma · collabOBiS, Inc · collabPPD Development, LP · collabQ2 Solutions · collabSteering Committee · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to test the hypothesis that patients with CML who have not achieved optimal response after 3 months of treatment with imatinib will have a better response by switching to dasatinib compared to staying on their original imatinib regimen.
Timeline
- Start
- 2012-09-12
- Primary completion
- 2017-11-08
- Completion
- 2022-04-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Imatinib | Small molecule | 400 mg | Oral |
| Comparator | dasatinib anhydrous | Small molecule | 100 mg | Oral |